UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,251	11/26/2003	Michael Dahlin	1039-0070	6060
	7590 05/14/200 MAN ABEL & POLA	EXAMINER		
5914 WEST CO	OURTYARD DRIVE	RANGREJ, SHEETAL		
SUITE 200 AUSTIN, TX 7	8730	ART UNIT	PAPER NUMBER	
			3686	
			MAIL DATE	DELIVERY MODE
			05/14/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Applica	tion No.	Applicant(s)		
		10/723	,251	DAHLIN ET AL.		
		Examin	er	Art Unit		
		SHEET	AL R. RANGREJ	3686		
 Period for	The MAILING DATE of this commun Reply	nication appears on t	he cover sheet with the	correspondence ad	ddress	
A SHOF WHICH - Extensic after SI2 - If NO pe - Failure t Any rep	RTENED STATUTORY PERIOD F EVER IS LONGER, FROM THE Nons of time may be available under the provisions (6) MONTHS from the mailing date of this comercial for reply is specified above, the maximum so reply within the set or extended period for reply by received by the Office later than three months patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE OF sof 37 CFR 1.136(a). In no munication. tatutory period will apply and will, by statute, cause the a	THIS COMMUNICATIO event, however, may a reply be till will expire SIX (6) MONTHS from application to become ABANDON	N. mely filed n the mailing date of this of ED (35 U.S.C. § 133).	·	
Status						
2a)⊠ T 3)□ S	esponsive to communication(s) file his action is <b>FINAL</b> . ince this application is in condition osed in accordance with the pract	2b)⊡ This action is for allowance exce	non-final. pt for formal matters, pr		e merits is	
Dispositio	ո of Claims					
4a 5) □ C 6) □ C 7) □ C 8) □ C	laim(s) 1-29 is/are pending in the above claim(s) is/a laim(s) is/a laim(s) is/are allowed. laim(s) 1-29 is/are rejected. laim(s) is/are objected to. laim(s) are subject to restrict the specification is objected to by the	are withdrawn from o				
10)⊠ Tr A R	ne drawing(s) filed on 22 January 2 pplicant may not request that any objected to by the eplacement drawing sheet(s) including the oath or declaration is objected to	2008 is/are: a)⊠ acetion to the drawing(s g the correction is requ	) be held in abeyance. Se uired if the drawing(s) is of	ee 37 CFR 1.85(a). ojected to. See 37 C	FR 1.121(d).	
Priority un	der 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2) Notice of 3) Informa	) of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (I tion Disclosure Statement(s) (PTO/SB/08) lo(s)/Mail Date	PTO-948)	4) Interview Summar Paper No(s)/Mail [ 5) Notice of Informal 6) Other:	Oate		

Art Unit: 3686 Page 2

#### **DETAILED ACTION**

## Prosecution History Summary

- Claims 1, 3-5, 7, 12-13, 15-16, 23, and 25-29 are amended.
- Claims 1-29 are pending.

### **Drawings**

1. The drawings were received on 01/22/2008. These drawings are accepted.

## Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. <u>Claims 1-3, 6, 8, 10, 12, 16-18, 20, 22-25, and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Iliff (U.S. Patent No. 5,935,060)</u>.
- 4. As per claim 1, Iliff teaches a method of providing a workflow interface, the method comprising:

-receiving <u>a baseline</u> template associated with a medical workflow step (Iliff: col. 4, 40-51; col. 20, 36-51);

Art Unit: 3686 Page 3

-receiving automated decision support data associated with the medical workflow step (Iliff: col. 6, 1-10);

- -integrating the <u>baseline</u> template and the automated decision support data into an interface page associated with the medical workflow step (Iliff: col. 20, 37-65); and
- -initiating presentation of the interface page on a display of an electronic device (Iliff: col. 4, 31-38).
- 5. As per claim 2, the method of claim 1 is as described. Iliff further teaches further comprising:
- -receiving patient finding data (Iliff: col. 4, 40-51); and
- -basing selection of the automated decision support data at least partially on the patient finding data (Iliff: col. 19, 15-32).
- 6. As per claim 3, the method of claim 1 is as described. Iliff wherein integrating comprises sorting elements associated with the baseline template (Iliff: col. 21, 26-47).
- 7. As per claim 6, the method of claim 1 is as described. Iliff further teaches further comprising initiating presentation of decision support text on the display (Iliff: col. 3, 51-65).
- 8. As per claim 8, the method of claim 1 is as described. Iliff further teaches wherein the medical workflow step comprises recording a history of present illness (Iliff: col. 24, 10-31).
- 9. As per claim 10, the method of claim 1 is as described. Iliff further teaches wherein the medical workflow step comprises a diagnosis (Iliff: col. 1, 66 to col. 2, 13).
- 10. As per claim 12, Iliff teaches A device (Iliff: col. 4, 51-57) configured to display a user interface associated with a step in a medical workflow, the user interface comprising baseline

Art Unit: 3686 Page 4

template integrated with automated decision support data (Iliff: col. 20, 37-65), the <u>baseline</u> template and the automated decision support data being associated with the step in the medical workflow, the automated decision support data being based on medical finding data (Iliff: col. 19, 15-32).

- 11. As per claim 16, the device of claim 12 is as described. The citation for claim 16 is the same as claim 3.
- 12. As per claim 17, the device of claim 12 is as described. The citation for claim 17 is the same as claim 2.
- 13. As per claim 18, the device of claim 12 is as described. The citation for claim 18 is the same as claim 8.
- 14. As per claim 20, the device of claim 12 is as described. The citation for claim 20 is the same as claim 10.
- 15. As per claim 22, the device of claim 12 is as described. Iliff further teaches wherein the user interface device is a portable computational circuitry configured to communicate with a wireless network (Iliff: figure 1, 102).
- 16. As per claim 23, Iliff teaches a system comprising: -a processor (Iliff: col. 5, 12-20); and -a storage medium storing (Iliff: col. 5, 36-42).
- 17. System claims 23-25 repeat the subject matter of claims 1-3 rather than a series of steps. As the underlying process has been shown to be fully disclosed by the teachings of Iliff in the above rejection of claims 1-3, it is readily apparent that the Iliff reference includes a system to

Art Unit: 3686 Page 5

perform the recited functions. As such, these limitations are rejected for the same reasons provided in the rejection of claims 1-3 and incorporated herein.

18. System claim 28 repeats the subject matter of claim 6 rather than a series of steps. As the underlying process has been shown to be fully disclosed by the teachings of Iliff in the above rejection of claim 6, it is readily apparent that the Iliff reference includes a system to perform the recited functions. As such, these limitations are rejected for the same reasons provided in the rejection of claim 6 and incorporated herein.

# Claim Rejections - 35 USC § 103

- 19. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 20. <u>Claims 4-5, 7, 9-11, 13-15, 19, 21, 26-27, and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Iliff (U.S. Patent No. 5,935,060) in view of Campbell et al. (U.S. Patent No. 6,047,259).</u>
- 21. As per claim 4, the method of claim 1 is as described. Iliff does not teach wherein integrating comprises highlighting a portion of the baseline template.

Art Unit: 3686 Page 6

Campbell teaches <u>wherein integrating comprises</u> highlighting a portion of the <u>baseline</u> template (Campbell: figures 4-10). The examiner interprets the selection of bubbles to be the same as highlighting a portion of the template data.

One of ordinary skill in the art at the time the invention was made would have found it obvious to combine the teachings of Iliff with Campbell with the motivation of conducting interactive exams to help assist physicians in medical diagnosis (Campbell: col. 1, 23-26; col. 1, 53-60).

22. As per claim 5, the method of claim 1 is as described. Iliff does not teach wherein integrating comprises annotating a portion of the baseline template.

Campbell teaches <u>wherein integrating comprises</u> annotating a portion of the <u>baseline</u> template (Campbell: figures 4-10).

The motivation to combine the teachings is the same as claim 4.

23. As per claim 7, the method of claim 1 is as described. Iliff does not teach wherein integrating comprises adding additional template elements to the interface page.

Campbell teaches <u>wherein integrating comprises</u> adding additional template elements to the interface page (Campbell: figures 4-10).

The motivation to combine the teachings is the same as claim 4.

24. As per claim 9, the method of claim 1 is as described. Iliff does not teach wherein the medical workflow step comprises a review of systems.

Campbell teaches wherein the medical workflow step comprises a review of systems (Campbell: figures 4-10).

Art Unit: 3686 Page 7

The motivation to combine the teachings is the same as claim 4.

25. As per claim 11, the method of claim 1 is as described. Iliff does not teach wherein the medical workflow step comprises a prescription writing step.

Campbell teaches wherein the medical workflow step comprises a prescription writing step (Campbell: col. 8, 29-41).

The motivation to combine the teachings is the same as claim 4.

- 26. As per claim 13, the device of claim 12 is as described. The citation and motivation of claim 13 is the same as claim 5.
- 27. As per claim 14, the device of claim 12 is as described. The citation and motivation of claim 14 is the same as claim 7.
- 28. As per claim 15, the device of claim 12 is as described. The citation and motivation of claim 15 is the same as claim 4.
- 29. As per claim 21, the device of claim 12 is as described. The citation and motivation of claim 21 is the same as claim 11.
- 30. As per claim 26, the system of claim 23 is as described. The citation and motivation of claim 26 is the same as claim 5.
- 31. As per claim 27, the system of claim 23 is as described. The citation and motivation of claim 27 is the same as claim 5.
- 32. As per claim 29, the system of claim 23 is as described. The citation and motivation of claim 29 is the same as claim 7.

Art Unit: 3686 Page 8

#### Conclusion

33. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

34. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

35. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHEETAL R. RANGREJ whose telephone number is (571) 270-1368. The examiner can normally be reached on M-F 8:30-5:30.

Art Unit: 3686 Page 9

36. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jerry O'Connor can be reached on (571) 272-6787. The fax phone number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you

would like assistance from a USPTO Customer Service Representative or access to the

automated information system, call 800-786-9199 (IN USA OR CANADA) or (571) 272-1000.

/S. R. R./

Examiner, Art Unit 3686

May 11, 2009

/Gerald J. O'Connor/ Supervisory Patent Examiner Group Art Unit 3686